BeStock  
Stocks › Biotechnology › ARDX

Ardelyx ARDX

US equityMarket cap rank #3373Biotechnology
$3.26 −$0.05 (-1.51%)
Market closed · Oct 8, 7:10 am ET · Last extended-hours $3.28 +0.61%
Open$3.26
Prev close$3.31
Day range$3.22 – $3.35
Volume5.39M
Market cap$841.69M
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

Technical signals

Trend readStrong downtrend

1 bullish · 5 bearish of 7 signals

IndicatorValueSignalReading
Price vs 20-day average-5.1%BearishTrading below the 20-day average of $3.43
Price vs 50-day average-15.3%BearishTrading below the 50-day average of $3.85
Price vs 200-day average-41.8%BearishTrading below the 200-day average of $5.60
50-day vs 200-day50d below 200dBearishThe 50-day average is below the 200-day average
RSI (14)29.9NeutralOversold territory (30 or below); selling this heavy often eases
MACD (12,26,9)-0.15BullishMACD line is above its signal line
Bollinger band position4%BearishInside the 20-day bands

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

Levels & volatility

Moving averages

AverageLevelPrice vs. it
20-day SMA$3.43-5.1%
50-day SMA$3.85-15.3%
200-day SMA$5.60-41.8%

Recent price levels

LevelPrice
20-day high$3.78
20-day low$3.22
60-day high$5.32
60-day low$3.22
Upper Bollinger band$3.62
Lower Bollinger band$3.24

The 50-day average is currently 31.2% below the 200-day average — consistent with a “death cross” (bearish) configuration.

30-day volatility28.8%
Average true range3.81% of price
Max drawdown (1y)-59.2%
Volume (10d vs 90d)0.97x

Discussion

No comments yet — be the first to weigh in on ARDX.

Leave a comment

Scroll to Top